Abstract
Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, but its pathogenesis has not been fully discovered. From the cellular perspective, CD133+ stem cells orchestrate the proliferation and development of IH. Regarding molecular mechanisms, hypoxia inducible factor-1α, renin-angiotensin system, and vascular endothelial growth factor are current study hotspots, while non-coding RNAs (ncRNAs) might be essential factors participating in this network. Therefore, this article reviewed published studies concerning the roles of ncRNAs in IH and listed noted miRNAs, lncRNAs, and circRNAs. Other ncRNAs, such as snRNAs, snoRNAs, and tsRNAs, though have not been examined in IH, are mentioned as well to discuss their potential functions. Due to the continuous development of sequencing technologies and computational pipelines for ncRNAs annotation, relevant studies will provide evidence to gradually enhance acknowledgments of ncRNAs’ role in IH. The pathogenesis of IH might be revealed and the treatment protocol would be optimized in the future.
Impact
-
Non-coding RNAs (ncRNAs) play critical roles in infantile hemangioma. This article thoroughly reviewed all ncRNAs (miRNAs, lncRNAs, and circRNAs) mentioned in previous studies regarding the pathogenesis of infantile hemangioma. Other ncRNAs are promising subjects for further investigation. This review introduced the emerging ncRNAs that need to be explored in IH.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 14 print issues and online access
$259.00 per year
only $18.50 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Solman, L. et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for paediatric dermatology consensus guidelines. Br. J. Dermatol. 179, 582–589 (2018).
Wu, H. W. et al. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front. Oncol. 8, 605 (2018).
Liu, C., Zhao, Z., Ji, Z., Jiang, Y. & Zheng, J. Mir-187-3p enhances propranolol sensitivity of hemangioma stem cells. Cell Struct. Funct. 44, 41–50 (2019).
Wang, Q. Z., Zhao, Z. L., Liu, C. & Zheng, J. W. Exosome-derived Mir-196b-5p facilitates intercellular interaction in infantile hemangioma via down-regulating Cdkn1b. Ann. Transl. Med. 9, 394 (2021).
Leaute-Labreze, C. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 372, 735–746 (2015).
Bayart, C. B., Tamburro, J. E., Vidimos, A. T., Wang, L. & Golden, A. B. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr. Dermatol. 34, 413–421 (2017).
Liu, C. et al. Exosomal Mir-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma. Cell Immunol. 370, 104442 (2021).
Shah, S. D. et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics 137, e20151754 (2016).
Léauté-Labrèze, C., Harper, J. I. & Hoeger, P. H. Infantile haemangioma. Lancet 390, 85–94 (2017).
Khan, Z. A. et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J. Clin. Invest. 118, 2592–2599 (2008).
North, P. E. et al. A unique microvascular phenotype shared by Juvenile hemangiomas and human placenta. Arch. Dermatol. 137, 559–570 (2001).
Rodriguez Bandera, A. I., Sebaratnam, D. F., Wargon, O. & Wong, L. F. Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment. J. Am. Acad. Dermatol. 85, 1379–1392 (2021).
Diederichs, S. Non-coding Rna and disease. RNA Biol. 9, 701–702 (2012).
Yan, H. & Bu, P. Non-coding Rna in cancer. Essays Biochem. 65, 625–639 (2021).
Matsui, M. & Corey, D. R. Non-coding Rnas as drug targets. Nat. Rev. Drug Discov. 16, 167–179 (2017).
Cech, T. R. & Steitz, J. A. The noncoding Rna revolution-trashing old rules to forge new ones. Cell 157, 77–94 (2014).
Li, Y. et al. Non-coding Rna in bladder cancer. Cancer Lett. 485, 38–44 (2020).
Qu, L. et al. Circular Rna vaccines against Sars-Cov-2 and emerging variants. Cell 185, 1728–1744.e1716 (2022).
Hong, D. S. et al. Phase 1 study of Mrx34, a liposomal Mir-34a Mimic, in patients with advanced solid tumours. Br. J. Cancer 122, 1630–1637 (2020).
Wu, X., Xiao, Y., Ma, J. & Wang, A. Circular Rna: a novel potential biomarker for skin diseases. Pharm. Res. 158, 104841 (2020).
Lee, R. C., Feinbaum, R. L., Ambros, V. & The, C. Elegans heterochronic gene Lin-4 encodes small rnas with antisense complementarity to Lin-14. Cell 75, 843–854 (1993).
Herter, E. K. & Xu Landen, N. Non-coding Rnas: new players in skin wound healing. Adv. Wound Care (N. Rochelle) 6, 93–107 (2017).
Bail, S. et al. Differential regulation of microrna stability. Rna 16, 1032–1039 (2010).
Liu, H. et al. Colorectal cancer-derived exosomal Mir-106b-3p promotes metastasis by down-regulating Dlc-1 expression. Clin. Sci. (Lond.) 134, 419–434 (2020).
Du, J. et al. Gastric cancer cell-derived exosomal microrna-23a promotes angiogenesis by targeting Pten. Front Oncol. 10, 326 (2020).
van der Ree, M. H. et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microrna-122 levels without affecting other micrornas in plasma. Aliment Pharm. Ther. 43, 102–113 (2016).
He, B. et al. Mirna-based biomarkers, therapies, and resistance in cancer. Int. J. Biol. Sci. 16, 2628–2647 (2020).
Wu, Z. B., Shi, S. L., Pan, F. J., Li, L. & Chen, H. Y. Propranolol inhibits infantile hemangioma by regulating the Mir-424/vascular endothelial growth factor-a (Vegfa) axis. Transl. Pediatr. 10, 1867–1876 (2021).
Fei, Z. et al. Microrna424 suppresses the proliferation of hemangiomaderived endothelial cells by targeting Vegfr2. Mol. Med. Rep. 18, 4065–4071 (2018).
Yang, L. et al. The expression and function of Mir-424 in infantile skin hemangioma and its mechanism. Sci. Rep. 7, 11846 (2017).
Li, M. M. et al. Lncrna-Malat1 promotes tumorogenesis of infantile hemangioma by competitively binding Mir-424 to stimulate Mekk3/Nf-Kappab pathway. Life Sci. 239, 116946 (2019).
Mong, E. F. et al. Modulation of Lin28b/Let-7 signaling by propranolol contributes to infantile hemangioma involution. Arterioscler Thromb. Vasc. Biol. 38, 1321–1332 (2018).
Rybak, A. et al. A feedback loop comprising Lin-28 and Let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat. Cell Biol. 10, 987–993 (2008).
Chang, L. et al. Infantile hemangioma: factors causing recurrence after propranolol treatment. Pediatr. Res. 83, 175–182 (2018).
Wang, S. J. et al. Long non-coding Rna 00152 slicing represses the growth and aggressiveness of hemangioma cell by modulating Mir-139-5p. Biomed. Pharmacother. Biomed. Pharmacother. 120, 109385 (2019).
Wu, Y. et al. Mir1395p affects cell proliferation, migration and adipogenesis by targeting insulinlike growth factor 1 receptor in hemangioma stem cells. Int. J. Mol. Med. 45, 569–577 (2020).
Yuan, X., Xu, Y., Wei, Z. & Ding, Q. Circap2a2 acts as a cerna to participate in infantile hemangiomas progression by sponging Mir-382-5p via regulating the expression of vegfa. J. Clin. Lab Anal. 34, e23258 (2020).
Li, D., Li, P., Guo, Z., Wang, H. & Pan, W. Downregulation of Mir-382 by propranolol inhibits the progression of infantile hemangioma via the pten-mediated Akt/Mtor pathway. Int. J. Mol. Med. 39, 757–763 (2017).
Wu, M. et al. Mir-206 promotes extracellular matrix accumulation and relieves infantile hemangioma through targeted inhibition of Dnmt3a. Cell Cycle 20, 978–992 (2021).
Wang, S., Ren, L., Shen, G., Liu, M. & Luo, J. The knockdown of Malat1 inhibits the proliferation, invasion and migration of hemangioma endothelial cells by regulating Mir-206/Vegfa Axis. Mol. Cell Probes 51, 101540 (2020).
Anand, S. et al. Microrna-132-mediated loss of P120rasgap activates the endothelium to facilitate pathological angiogenesis. Nat. Med. 16, 909–914 (2010).
Biswas, A. et al. Urinary excretion of microrna-126 is a biomarker for hemangioma proliferation. Plast. Reconstr. Surg. 139, 1277e–1284e (2017).
Strub, G. M. et al. Endothelial and circulating C19mc micrornas are biomarkers of infantile hemangioma. JCI Insight 1, e88856 (2016).
Wang, Y. et al. Long noncoding Rna Dscam-As1 facilitates proliferation and migration of hemangioma endothelial cells by targeting Mir-411-5p/Tpd52 axis. Biomed. Res. Int. 2022, 8696432 (2022).
Peng, K. et al. Alkbh5 promotes the progression of infantile hemangioma through regulating the Neat1/Mir-378b/Fosl1 axis. Mol. Cell Biochem. 477, 1527–1540 (2022).
Fu, C., Yang, K., Zou, Y. & Huo, R. Identification of key micrornas and genes in infantile hemangiomas. Front. Genet. 13, 766561 (2022).
Chen, H. & Li, Y. Circular Rna Hsa_Circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas. Hum. Genom. 16, 43 (2022).
Zhou, L., Jia, X. & Yang, X. Lncrna-Tug1 promotes the progression of infantile hemangioma by regulating Mir-137/Igfbp5 axis. Hum. Genom. 15, 50 (2021).
Hu, Z. et al. Knockdown of Lncrna Meg8 inhibits cell proliferation and invasion, but promotes cell apoptosis in hemangioma, via Mir203induced mediation of the notch signaling pathway. Mol. Med. Rep. 24, 872 (2021).
Hu, X. et al. Mir-200c-3p increased hdmec proliferation through the notch signaling pathway. Exp. Biol. Med. 246, 897–905 (2021).
Zeng, Z., Chen, H., Cai, J., Huang, Y. & Yue, J. Il-10 regulates the malignancy of hemangioma-derived endothelial cells via regulation of Pcna. Arch. Biochem Biophys. 688, 108404 (2020).
Yu, L. et al. Silencing long noncoding Rna Neat1 suppresses the tumorigenesis of infantile hemangioma by competitively binding Mir33a5p to stimulate Hif1alpha/Nfkappab pathway. Mol. Med. Rep. 22, 3358–3366 (2020).
Zeng, Z. et al. Mir-501 promotes hemangioma progression by targeting Hoxd10. Am. J. Transl. Res. 11, 2439–2446 (2019).
Yu, X., Liu, X., Wang, R. & Wang, L. Long non-coding Rna Neat1 promotes the progression of hemangioma via the Mir-361-5p/Vegfa pathway. Biochem. Biophys. Res. Commun. 512, 825–831 (2019).
Lu, S., Chen, L. & Tang, L. Upregulation of Akt1 and downregulation of Akt3 caused by dysregulation of micrornas contributes to pathogenesis of hemangioma by promoting proliferation of endothelial cells. J. Cell. Physiol. 234, 21342–21351 (2019).
Liu, Z., Kang, Z., Dai, Y., Zheng, H. & Wang, Y. Long noncoding Rna Linc00342 promotes growth of infantile hemangioma by sponging Mir-3619-5p from Hdgf. Am. J. Physiol. Heart Circ. Physiol. 317, H830–H839 (2019).
Huang, C., Huang, J., Ma, P. & Yu, G. Microrna-143 acts as a suppressor of hemangioma growth by targeting Bcl-2. Gene 628, 211–217 (2017).
Kopp, F. & Mendell, J. T. Functional classification and experimental dissection of long noncoding Rnas. Cell 172, 393–407 (2018).
Zhao, Y. et al. Noncode 2016: an informative and valuable data source of long non-coding Rnas. Nucleic Acids Res. 44, D203–D208 (2016).
Ulitsky, I. & Bartel, D. P. Lincrnas: genomics, evolution, and mechanisms. Cell 154, 26–46 (2013).
Liu, S. J. et al. Crispri-based genome-scale identification of functional long noncoding Rna Loci in human cells. Science 355, aah7111 (2017).
Yang, W. et al. Lncrna Brcat54 inhibits the tumorigenesis of non-small cell lung cancer by binding to Rps9 to transcriptionally regulate Jak-Stat and calcium pathway genes. Carcinogenesis 42, 80–92 (2021).
Lv, Z., Yang, K. & Wang, Y. Long non-coding Rna breast cancer-associated transcript 54 sponges microrna-1269b to suppress the proliferation of hemangioma-derived endothelial cells. Bioengineered 13, 6188–6195 (2022).
Wen, S. et al. Long non-coding Rna Neat1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Mol. Cancer 19, 171 (2020).
Ji, P. et al. Malat-1, a novel noncoding Rna, and thymosin Beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031–8041 (2003).
Ma, Q. et al. Silencing long non-coding Rna Meg8 inhibits the proliferation and induces the ferroptosis of hemangioma endothelial cells by regulating Mir-497-5p/Notch2 Axis. Biochem. Biophys. Res. Commun. 556, 72–78 (2021).
Wu, J. K. et al. A switch in notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis 13, 15–23 (2010).
Wang, Y. et al. Linc00152 knockdown inactivates the Akt/Mtor and Notch1 pathways to exert its anti-hemangioma effect. Life Sci. 223, 22–28 (2019).
Lee, J. C., Modiri, O., England, R. W., Shawber, C. J. & Wu, J. K. Propranolol therapy in infantile hemangioma: it is not just about the beta. Plast. Reconstr. Surg. 147, 875–885 (2021).
Li, X. et al. Linking circular intronic Rna degradation and function in transcription by Rnase H1. Sci. China Life Sci. 64, 1795–1809 (2021).
Xu, X. et al. Circrna inhibits DNA damage repair by interacting with host gene. Mol. Cancer 19, 128 (2020).
Piwecka, M. et al. Loss of a mammalian circular Rna locus causes mirna deregulation and affects brain function. Science 357, eaam8526 (2017).
Fu, C. et al. Circular Rna profile of infantile hemangioma by microarray analysis. PloS One 12, e0187581 (2017).
Li, Z. et al. Circular Rna expression profiles in the plasma of patients with infantile hemangioma determined using microarray analysis. Exp. Ther. Med. 21, 634 (2021).
Li, J., Li, Q., Chen, L., Gao, Y. & Li, J. Expression Profile of Circular Rnas in Infantile Hemangioma Detected by Rna-Seq. Med. (Baltim.) 97, e10882 (2018).
Tian, Y. et al. Geo database screening combined with in vitro experiments to study the mechanism of Hsa_Circ_0003570 in infantile hemangiomas. Comput Math. Methods Med. 2022, 5643742 (2022).
Gu, D., Lou, H., Li, Y. & Xu, G. Identification of a functional circrna-mirna-mrna regulatory network in infantile hemangioma by bioinformatics analysis. Med. (Baltim.) 101, e30791 (2022).
Ruszkowska, A. Mettl16, methyltransferase-like protein 16: current insights into structure and function. Int. J. Mol. Sci. 22, 2176 (2021).
Morais, P., Adachi, H. & Yu, Y. T. Spliceosomal snrna epitranscriptomics. Front. Genet. 12, 652129 (2021).
Suzuki, H. et al. Recurrent noncoding U1 snrna mutations drive cryptic splicing in shh medulloblastoma. Nature 574, 707–711 (2019).
Xiao, L., Wang, J., Ju, S., Cui, M. & Jing, R. Disorders and roles of tsrna, snorna, snrna and pirna in cancer. J. Med. Genet. 59, 623–631 (2022).
Romano, G., Veneziano, D., Acunzo, M. & Croce, C. M. Small non-coding Rna and cancer. Carcinogenesis 38, 485–491 (2017).
Wajahat, M., Bracken, C. P. & Orang, A. Emerging functions for snornas and snorna-derived fragments. Int. J. Mol. Sci. 22, 10193 (2021).
Zheng, D. et al. Small nucleolar Rna 78 promotes the tumorigenesis in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 34, 49 (2015).
Lee, Y. S., Shibata, Y., Malhotra, A. & Dutta, A. A novel class of small Rnas: Trna-derived Rna fragments (Trfs). Genes Dev. 23, 2639–2649 (2009).
Chen, Q., Zhang, X., Shi, J., Yan, M. & Zhou, T. Origins and evolving functionalities of Trna-derived small Rnas. Trends Biochem. Sci. 46, 790–804 (2021).
Xie, Y. et al. Action mechanisms and research methods of Trna-derived small Rnas. Signal Transduct. Target Ther. 5, 109 (2020).
Xiong, Q., Zhang, Y., Li, J. & Zhu, Q. Small non-coding rnas in human cancer. Genes (Basel) 13, 2072 (2022).
Gu, W. et al. Peripheral blood non-canonical small non-coding Rnas as novel biomarkers in lung cancer. Mol. Cancer 19, 159 (2020).
Acknowledgements
The figures were drawn using BioRender online software.
Author information
Authors and Affiliations
Contributions
All authors contributed to the content discussion. Study conception and design were performed by Qizhang Wang and Jian Pan. The first draft of the manuscript was written by Qizhang Wang. Data acquisition and analysis were performed by Chengzhi Zhao, Qianxin Du, and Zhiwei Cao. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, Q., Zhao, C., Du, Q. et al. Non-coding RNA in infantile hemangioma. Pediatr Res (2024). https://doi.org/10.1038/s41390-024-03250-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41390-024-03250-z